静脉铁治疗:既往不良反应后再次给药。

IF 1.4 Q4 PRIMARY HEALTH CARE
Korean Journal of Family Medicine Pub Date : 2023-11-01 Epub Date: 2023-08-18 DOI:10.4082/kjfm.23.0039
Tim Aung, Hla Thein, Sandy Tin Aung, Benjamin Tin Aung Soe, Ei Ohnmar
{"title":"静脉铁治疗:既往不良反应后再次给药。","authors":"Tim Aung, Hla Thein, Sandy Tin Aung, Benjamin Tin Aung Soe, Ei Ohnmar","doi":"10.4082/kjfm.23.0039","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Intravenous (IV) iron therapy is performed in community practices and hospitals with modern formulations when oral administration becomes impractical. Effective replacement of iron is important for the treatment of iron deficiency and anemia. Can IV iron be rechallenged in individuals with a history of adverse reactions? This review is to explore the challenge of this, when clinically indicated.</p><p><strong>Methods: </strong>After performing a literature search, five studies (combined total sample number=1,006) for re-exposure of IV iron to individuals with a history of past reactions were identified, observed, and analyzed. Re-exposure included reactions ranging from mild to moderate and few cases of severe type.</p><p><strong>Results: </strong>The majority (>80%) of IV iron rechallenges were tolerable, safe, and successful without major serious incidents. There were no reports of major reactions (severe hypersensitivity reactions or anaphylaxis) in these re-exposures.</p><p><strong>Conclusion: </strong>Re-administration of IV iron therapy in patients with a previous adverse reaction is plausible, with benefit and risk stratification. A rechallenge would depend on the nature and degree of the adverse reaction and use of alternative formulations. Rechallenge to a previous severe hypersensitivity reaction or anaphylaxis with the same product has not been reported in these studies. Evidence on the benefit of premedication use is conflicting and requires further studies.</p>","PeriodicalId":17893,"journal":{"name":"Korean Journal of Family Medicine","volume":" ","pages":"350-354"},"PeriodicalIF":1.4000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667078/pdf/","citationCount":"0","resultStr":"{\"title\":\"Intravenous Iron Therapy: Re-administration after Prior Adverse Reaction.\",\"authors\":\"Tim Aung, Hla Thein, Sandy Tin Aung, Benjamin Tin Aung Soe, Ei Ohnmar\",\"doi\":\"10.4082/kjfm.23.0039\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Intravenous (IV) iron therapy is performed in community practices and hospitals with modern formulations when oral administration becomes impractical. Effective replacement of iron is important for the treatment of iron deficiency and anemia. Can IV iron be rechallenged in individuals with a history of adverse reactions? This review is to explore the challenge of this, when clinically indicated.</p><p><strong>Methods: </strong>After performing a literature search, five studies (combined total sample number=1,006) for re-exposure of IV iron to individuals with a history of past reactions were identified, observed, and analyzed. Re-exposure included reactions ranging from mild to moderate and few cases of severe type.</p><p><strong>Results: </strong>The majority (>80%) of IV iron rechallenges were tolerable, safe, and successful without major serious incidents. There were no reports of major reactions (severe hypersensitivity reactions or anaphylaxis) in these re-exposures.</p><p><strong>Conclusion: </strong>Re-administration of IV iron therapy in patients with a previous adverse reaction is plausible, with benefit and risk stratification. A rechallenge would depend on the nature and degree of the adverse reaction and use of alternative formulations. Rechallenge to a previous severe hypersensitivity reaction or anaphylaxis with the same product has not been reported in these studies. Evidence on the benefit of premedication use is conflicting and requires further studies.</p>\",\"PeriodicalId\":17893,\"journal\":{\"name\":\"Korean Journal of Family Medicine\",\"volume\":\" \",\"pages\":\"350-354\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2023-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667078/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Korean Journal of Family Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4082/kjfm.23.0039\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/8/18 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"PRIMARY HEALTH CARE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Korean Journal of Family Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4082/kjfm.23.0039","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/18 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PRIMARY HEALTH CARE","Score":null,"Total":0}
引用次数: 0

摘要

背景:当口服给药变得不切实际时,在社区实践和医院使用现代配方进行静脉(IV)铁治疗。有效补充铁对于治疗缺铁和贫血很重要。有不良反应史的患者可以重新注射铁吗?本综述旨在探讨临床适应症时的挑战。方法:通过文献检索,对有既往反应史的个体再暴露IV铁的5项研究(合计总样本数= 1006)进行鉴定、观察和分析。再暴露包括轻度至中度反应,少数病例为重度反应。结果:大多数(>80%)静脉补铁是可耐受的、安全的、成功的,无重大严重事件发生。在这些再暴露中没有主要反应(严重超敏反应或过敏反应)的报告。结论:对既往不良反应的患者再次给予静脉铁治疗是合理的,有获益和风险分层。重新提出质疑将取决于不良反应的性质和程度以及替代制剂的使用情况。在这些研究中,未见用同一产品再次发生严重超敏反应或过敏反应的报道。关于药物前使用的益处的证据是相互矛盾的,需要进一步的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Intravenous Iron Therapy: Re-administration after Prior Adverse Reaction.

Background: Intravenous (IV) iron therapy is performed in community practices and hospitals with modern formulations when oral administration becomes impractical. Effective replacement of iron is important for the treatment of iron deficiency and anemia. Can IV iron be rechallenged in individuals with a history of adverse reactions? This review is to explore the challenge of this, when clinically indicated.

Methods: After performing a literature search, five studies (combined total sample number=1,006) for re-exposure of IV iron to individuals with a history of past reactions were identified, observed, and analyzed. Re-exposure included reactions ranging from mild to moderate and few cases of severe type.

Results: The majority (>80%) of IV iron rechallenges were tolerable, safe, and successful without major serious incidents. There were no reports of major reactions (severe hypersensitivity reactions or anaphylaxis) in these re-exposures.

Conclusion: Re-administration of IV iron therapy in patients with a previous adverse reaction is plausible, with benefit and risk stratification. A rechallenge would depend on the nature and degree of the adverse reaction and use of alternative formulations. Rechallenge to a previous severe hypersensitivity reaction or anaphylaxis with the same product has not been reported in these studies. Evidence on the benefit of premedication use is conflicting and requires further studies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Korean Journal of Family Medicine
Korean Journal of Family Medicine PRIMARY HEALTH CARE-
CiteScore
4.00
自引率
4.30%
发文量
51
审稿时长
53 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信